The outside read
Not because anyone lies to you. Because every answer arrives from a position: years on you, a budget to protect, numbers to defend.
So we read the record before you walk in: tenders, awards, filings, registries, payer documents. One therapy area, one geography per report. Every line named, sourced and checkable. Your first leadership meeting shifts from asking to assessing.
What clients say
This report serves as a strategic compass, transforming a complex landscape into a clear, prioritised execution plan. It moves the commercial function from a reactive footing to a proactive one: identifying where you can influence specifications before they become live tenders.
One of the most comprehensive and precise analyses I have encountered. Its greatest strength lies in the clarity and practicality of its recommendations. The emphasis on well-defined, executable actions materially enhances its value, enabling a direct transition from analysis to implementation.
Every new commercial leader gets the same advice: listen for ninety days. The room does not wait ninety days. Respect in a senior meeting is settled early and defended afterwards, and the transition research measures everything except the ninety minutes in which that room decides what it thinks of you.
We wrote about exactly this in the newsletter: one commercial director, three business units he had never run, and a single question about a twelve million pound contract that changed the meeting before it started.
What this is
A commissioned intelligence report on a single commercial market: sixteen sections covering competitor activity, procurement, regulation, reimbursement, private healthcare, talent movement, and financial signals. Three specific actions for the next ninety days arrive at section two, near the front, where you will actually read them. Every claim carries a named source with a date. Anything the research couldn't verify is declared absent, not estimated: every report includes a “What Is Not In This Report and Why” statement.
Each report covers one commercial market in one geography. Multi-market assignments are scoped per report at the same unit price.
Inside the report
Section two of every report, not a conclusion buried at the back. It sets out three specific actions ranked by commercial urgency, each classified RED, AMBER, or GREEN, each stating the intelligence behind it and the cost of not acting. If you read one section, read this one and decide whether you agree.
Where the contracts went, who bid, who didn't, and which windows open next. The award notice usually tells you more one layer down than it does in the headline.
The people moving are the leading indicator of where the strategy is going. A new VP Sales at a competitor is rarely just a new VP Sales.
What changed, which products it touches, and what to brief your team on before it becomes a problem in the field.
The market outside the public system: privately insured activity, private hospital groups, self-pay, and independent procurement. Present in every report, every geography.
Who actually signs in your accounts, what each of them fears, and the line that opens them. The one section a sample can never show you, because it's researched for your territory.
Also inside: executive summary, market snapshot, major announcements, M&A and investment, clinical evidence, reimbursement and payer intelligence, key opinion leaders, digital and promotional activity, horizon intelligence, and earnings signals.
Read before you buy
Each sample is a working excerpt of a real report: same sections, same source discipline, same standard of read. What it cannot show you is the part built around your accounts, your competitive set, and the questions you bring to the brief. The samples say so on the page where it applies, and so do we.
An 18.4% tariff cut with no competitive process to resist it, a premium lens market locked out of the NHS four separate ways, and €0.5bn of capital backing the side of the wall that scales. Every claim named, sourced and checkable.
Read the sampleTwo FDA clearances thirteen days apart, a third in review, and the lock-in clock running on 431 placements a quarter. The read on a window that closes account by account. Every claim named, sourced and checkable.
Read the sampleThe Day One Brief
Every senior appointment that went past an internal candidate creates two people: the one who got the job, and the one who wanted it and will be sitting at the table on Monday. The Day One Brief exists for that Monday. Five questions about the new market, each with the evidence behind it, delivered the Friday before the first meeting rather than discovered somewhere in the first quarter.
The new leader walks in asking questions the room cannot comfortably answer, instead of defending an appointment. A commercial leader who helped shape the product put it more directly: it makes your new hire look like a superhero in their first month.
Commissioned by the hiring company or the incoming leader. Scoped on a call.
Defensible in the room
Internal briefings are written by people with careers. They soften what looks bad, or they have been in the market so long they cannot see it any more. This report comes from outside, with no stake in what it finds and no filter between the evidence and the page. And because every claim names its public source and the date it was published, you can put it in front of a board, a procurement team or a value analysis committee without a single line you cannot defend.
Who it's for
For
Founders, CEOs, MDs, VPs of Sales and Marketing, Market Access Directors, and Commercial Directors in medical devices across the UK, US, and Europe, who already know their market and need to know what's moving in it, or who are walking into a market they've never sold in.
Not for
Anyone wanting a primer on a therapy area, a generic sector overview, or a data platform. Enterprise platforms write for markets. This is written for you, at your company, for the decisions you're making this quarter.
What it stands on
Nothing in the report is secret. It sits in procurement portals, regulatory databases, Companies House filings, clinical registers, tender awards and board papers, roughly a hundred separate public signals, and every one of them is available to anyone who knows where to look and has two weeks to spare. You don't.
Each source on its own says almost nothing. Read together, in order, they show you which three things in your market are about to matter and which are noise. Every claim carries the name of the source it came from and the date it was published. Where the record is silent, the report says so. No estimates dressed as findings. You can check any line of it against the source printed beside it.
The price
£7,000 €8,000 $9,500
Per report, per commission. No tiers, no lock-in, no annual commitment. Each report covers one commercial market in one geography. Delivered within five working days of commission. Payment by Stripe or bank transfer; invoice issued automatically.
Multi-market assignments run as a programme: each report at the same unit price, sequenced to your calendar, with a cross-market read comparing every geography included in the final delivery. Entering three countries buys you three reports and the view across all three that none of them can hold alone.
Wider distribution across a team or function, and standing arrangements across a year, are scoped on a call.
Questions
About the report
A commissioned commercial intelligence report on a single medical device market: sixteen sections, every claim carrying a named source and date, with three prioritised actions for the next ninety days at section two rather than at the back. It's built for a named reader making specific decisions, not for a category.
Every retained search starts with a detailed read of the market: who is hiring, who has been funded, who is building ahead of a launch. The reports began as something built for the executives we placed, so they arrived already knowing the market they were walking into. Enough clients asked to buy them on their own that they now stand as a product in their own right.
Any medical device commercial market in the UK, US, or Europe. Each report covers one commercial market in one geography. Multi-market assignments are scoped per report at the same unit price.
A five-question brief for an incoming commercial leader, delivered before their first Monday: the questions worth walking in with, each backed by evidence from the public record. Commissioned by the hiring company or the leader themselves, and scoped on a call.
Buying
£7,000 / €8,000 / $9,500 per report, per commission. No tiers, no lock-in. Payment by Stripe with an automatic invoice, or by bank transfer where card payment doesn't suit procurement: email blair.anderson@innotechrecruit.com for a proforma invoice.
Yes. Two working excerpts of real reports are on this page, one UK and one US: same sections, same source discipline, same standard of read. The part they cannot show you is the part built for you: the buyer map, the named contacts, and the actions researched for your accounts and your territory.
Each report is licensed to the commissioning reader. Short extracts may be cited internally with attribution. For distribution across a team or function, email Blair Anderson: wider licences and standing arrangements are scoped on a call.
Delivery
Five working days from commission, confirmed in your order confirmation. If anything moves the date, Blair Anderson contacts you before it's due.
As a PDF by email, directly from blair.anderson@innotechrecruit.com, named to you and marked confidential on the cover.
Sources and method
Structured research across regulatory databases, company filings, procurement frameworks, payer documents, clinical registers, and named trade press. Every source is listed by name and date at the end of every report, and anything the research couldn't verify is declared absent in the “What Is Not In This Report and Why” statement rather than estimated.
Yes. Research tools do the gathering, and every claim is then checked against the source it came from. Anything that can't be traced to a named source and a date is excluded rather than estimated.